CFO John Borgeson Executes Structured 10‑b‑5‑1 Trading Plan, Buying at $1.04 While Selling at $34, Signaling Long‑Term Confidence Amid Kodiak Sciences’ Volatile Stock Journey

Insider Activity Highlights a Strategic Shift

On June 4, 2026, Chief Financial Officer John A. Borgeson executed a series of trades that paint a picture of a manager actively managing his equity position while also providing liquidity for the company. He purchased 30 000 shares at $1.04, raising his stake to 241 930 shares, and simultaneously sold 25 896 shares at an average of $34.01, followed by a smaller sale of 4 104 shares at $34.67. These transactions were all carried out under a 10‑b‑5‑1 trading plan adopted in September 2025, indicating that Borgeson is following a pre‑arranged schedule rather than reacting to short‑term market movements.

What Does This Mean for Investors?

The net effect of the day’s activity is a slight dilution of Borgeson’s holdings, but the overall trend over the past two months shows a gradual buildup of equity. This pattern suggests confidence in the company’s long‑term prospects, especially given the recent 2026 annual meeting approvals that reaffirmed executive compensation and governance. However, the simultaneous sales at higher prices could signal a strategic need for liquidity—perhaps to fund upcoming clinical trials or to maintain personal diversification. For investors, the key takeaway is that Borgeson’s trades are governed by a structured plan, reducing the risk of opportunistic selling and reinforcing his commitment to the company’s trajectory.

Borgeson’s Historical Trading Profile

Borgeson’s transaction history over the past twelve months illustrates a cautious yet deliberate approach. He has consistently sold shares in the $39–$42 range while buying around $1.04, indicating a disciplined use of a 10‑b‑5‑1 plan. Notably, he exercised a large block of 30 000 options in April 2026, converting them into cash, and has since been purchasing shares at the same $1.04 price point. His activity is punctuated by occasional option exercises, but these are spaced at least a year apart, underscoring a long‑term investment horizon. This behavior aligns with the expectations for a senior executive who balances personal financial planning with fiduciary responsibilities to shareholders.

Company‑Wide Insider Activity Context

While Borgeson’s trades dominate the recent filing, other insiders such as Chairman Victor Perlroth have been buying large blocks (300 000 shares) at $1.04, mirroring the CFO’s buying pattern. This cohort of executives appears to be consolidating positions at a low entry price, likely anticipating future upside as Kodiak’s clinical programs progress. The broader insider buying trend is a positive signal for investors, suggesting that those with the most intimate knowledge of the company’s operations remain bullish.

Strategic Implications for Kodiak Sciences

Kodiak’s stock has endured a steep decline over the past year, dropping 32% monthly and 15% weekly as of early June. Yet, the company’s fundamentals—its focus on chronic retinal diseases and a robust pipeline—continue to attract insider support. The CFO’s disciplined trading and the recent annual meeting approvals point toward a stable governance structure poised to navigate the next funding cycle. For investors, the prudent insider activity amid a volatile market implies that Kodiak may be positioning itself for a strategic turnaround, potentially driven by upcoming clinical data releases or partnership announcements.